JorgeGermanDarcourtMD

Oncology • Sugar Land, TX

Breast Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Darcourt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Darcourt's full profile

Already have an account?

Office
1350 First Colony Blvd
Sugar Land, TX 77479
Phone+1 281-277-5200

Fax+1 281-276-5201
Is this information wrong?

Education & Training

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2003 - 2006
University of Buenos AiresClass of 2000

Certifications & Licensure

TX State Medical License 2006 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Start of enrollment: 2011 Sep 01
Completed
Phase 2
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer Start of enrollment: 2012 Jul 01
Withdrawn
Phase 2
Olive Oil for High Risk Breast Cancer Prevention in Women Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Start of enrollment: 2014 Feb 01
Completed
Phase 2
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Start of enrollment: 2017 Apr 24
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer.
Kevin T Tran, Neil C Chevli, Jay A Messer, Waqar Haque, Andrew M Farach, Raj Satkunasivam, Jun Zhang, Jorge Darcourt, Simon S Lo, Shankar Siva, Edward B Butler, Bin S Teh> ;Clinical and Translational Radiation Oncology. 2023 Mar 1
3 citations
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Kai Sun, Yitian Xu, Licheng Zhang, Polly Niravath, Jorge Darcourt, Tejal Patel, Bin S Teh, Andrew M Farach, Carlo Guerrero, Sunil Mathur, Mark A Sultenfuss, Nakul Gupt...> ;Clinical Cancer Research. 2022 Oct 14
39 citations
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
Andrew W Chung, Kartik Anand, Ann C Anselme, Alfred A Chan, Nakul Gupta, Luz A Venta, Mary R Schwartz, Wei Qian, Yitian Xu, Licheng Zhang, John Kuhn, Tejal Patel, Ange...> ;Science Translational Medicine. 2021 Dec 15
5 citations
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Emre Koca, Polly A. Niravath, Joe Ensor, Tejal Patel, Xiaoxian Li, Pej Hemati, Helen Wong, Wei Qian, Toniva Boone, Jing Zhao, Priya V. Ramshesh, Adam L. Cohen, Asha Mu...> ;Breast Cancer Research and Treatment. 2021 Apr 15
14 citations
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.
Kartik Anand, Tejal Patel, Polly A. Niravath, Angel Rodriguez, Jorge Darcourt, Anna Belcheva, Toniva Boone, Joe Ensor, Jenny C. Chang> ;Scientific Reports. 2021 Jan 8
63 citations
Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic
Jorge Darcourt, Kalia Aparicio, Phillip M. Dorsey, Joe Ensor, Eva M Zsigmond, Stephen T. C. Wong, Chika F. Ezeana, Mamta Puppala, Kirk Heyne, Charles E. Geyer, Robert ...> ;JCO Oncology Practice. 2021 Jan 1
28 citations
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-...
Tejal Patel, Joe Ensor, Sarah L. Creamer, Toniva Boone, Angel Rodriguez, Polly A. Niravath, Jorge Darcourt, Jane L. Meisel, Xiaoxian Li, Jing Zhao, John G. Kuhn, Rober...> ;Breast Cancer Research. 2019 Sep 2
13 citations
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases.
Zhe Bin Liu, Nader E. Ezzedine, Agda Karina Eterovic, Joe Ensor, Helen J. Huang, Joan Albanell, Dong S. Choi, Ana Lluch, Yi Liu, Federico Rojo, Helen Wong, Eduardo Mar...> ;Breast Cancer Research and Treatment. 2019 Nov 1
4 citations
Short-term Mortality Associated with Definitive Chemoradiotherapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Waqar Haque, Vivek Verma, Monty A. Aghazadeh, Jorge Darcourt, E. Brian Butler, Bin S. Teh> ;Clinical Genitourinary Cancer. 2019 Jul 2
20 citations
The role of adjuvant chemotherapy in locally advanced bladder cancer.
Waqar Haque, Gary D. Lewis, Vivek Verma, Jorge Darcourt, E. Brian Butler, Bin S. Teh> ;Acta Oncologica. 2017 Dec 11
225 citations
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy.
Samuel A. Shelburne, Jorge Darcourt, A. Clinton White, Stephen B. Greenberg, Richard J. Hamill, Robert L. Atmar, Fehmida Visnegarwala> ;Clinical Infectious Diseases. 2005 Apr 1
469 citations
Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy
Samuel A. Shelburne, Fehmida Visnegarwala, Jorge Darcourt, Edward A. Graviss, Thomas P. Giordano, A. Clinton White, Richard J. Hamill> ;AIDS. 2005 Mar 4
1 citations
Changes in metabolic profile among antiretroviral-naive patients initiating protease inhibitor versus non-protease inhibitor containing HAART regimens.
Fehmida Visnegarwala, Jorge Darcourt, Prasuna Sajja, Vandana Menon, Oliver Ong, Mario Maldonado, A. Clinton White> ;Journal of Acquired Immune Deficiency Syndromes. 2003 Aug 15
Join now to see all

Press Mentions

Managing Cancer Care During COVID-19: 4 Oncologists Weigh InJuly 22nd, 2020
New Technology Reduces Chemotherapy-Related Hair Loss for Patients at Houston Methodist SL HospitalJanuary 31st, 2019
Olive Oil for High Risk Breast Cancer Prevention in WomenFebruary 21st, 2014
Join now to see all